To describe the antibacterial activity of treatment with riboflavin and ultraviolet A light (UVA) in cases of severe infectious keratitis.
Methods
A retrospective analysis was performed of an interventional case series in which 6 eyes of 6 patients with severe infectious keratitis, all of whom were refractive to multidrug conventional therapy, were treated with riboflavin/UVA. The procedure was conducted according to the standardized protocol of corneal collagen crosslinking (CXL) for keratoconus. Best spectacle-corrected visual acuity and clinical outcomes were evaluated before and during the follow-up period.
Results
Five of the 6 patients showed rapid reduction in symptoms and decreased infiltrate size after riboflavin/UVA photochemical therapy. Signs of infection and inflammation mostly resolved within 1 to 2 weeks after the treatment. Despite this therapy, one patient continued to deteriorate, and penetrating keratoplasty was performed.
Conclusions
The adjunctive use of riboflavin/UVA photochemical therapy has a positive effect on refractory infectious keratitis. The treatment seems to be safe and effective and should be considered as part of the first-line therapy in severe cases of infectious keratitis.
AshwinP.T., McDonnellP.J.. Collagen cross-linkage: a comprehensive review and directions for future research.Br J Ophthalmol2010; 94: 965–70.
2.
TsugitaA., OkadaY., UeharaK.. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin.Biochim Biophys Acta1965; 103: 360–3.
3.
KumarV., LockerbieO., KeilS.D.. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level.Photochem Photobiol2004; 80: 15–21.
4.
CorbinFIII. Pathogen inactivation of blood components: current status and introduction of an approach using riboflavin as a photosensitizer.Int J Hematol2002; 76(Suppl 2): 253–7.
5.
AuBuchonJ.P., HerschelL., RogerJ.. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.Transfusion2005; 45: 1335–41.
6.
MakdoumiK., BäckmanA., MortensenJ., CrafoordS.. Evaluation of antibacterial efficacy of photo-activated riboflavin using ultraviolet light (UVA).Graefes Arch Clin Exp Ophthalmol2010; 248: 207–12.
7.
MartinsS.A., CombsJ.C., NogueraG.. Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis.Invest Ophthalmol Vis Sci2008; 49: 3402–8.
8.
SchnitzlerE., SpörlE., SeilerT.. [Irradiation of cornea with ultraviolet light and riboflavin administration as a new treatment for erosive corneal processes, preliminary results in four patients.]Klin Monatsbl Augenheilkd2000; 217: 190–3.
9.
Micelli FerrariT., LeozappaM., LorussoM., EpifaniE., Micelli FerrariL.. Escherichia coli keratitis treated with ultraviolet A/riboflavin corneal cross-linking: a case report.Eur J Ophthalmol2009; 19: 295–7.
10.
IseliH.P., ThielM.A., HafeziF., KampmeierJ., SeilerT.. Ultraviolet A/riboflavin corneal cross-linking for infectious keratitis associated with corneal melts.Cornea2008; 27: 590–4.
11.
KhanY.A., KashiwabuchiR.T., MartinsS.A.. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis: report of 3 cases.Ophthalmology2011; 118: 324–31.
12.
KymionisG.D., PortaliouD.M., BouzoukisD.I.. Herpetic keratitis with iritis after corneal crosslinking with riboflavin and ultraviolet A for keratoconus.J Cataract Refract Surg2007; 33: 1982–4.
13.
MorénH., MalmsjöM., MortensenJ., OhrströmA.. Riboflavin and ultraviolet A collagen crosslinking of the cornea for the treatment of keratitis.Cornea2010; 29: 102–4.
14.
SpoerlE., SeilerT.. Techniques for stiffening the cornea.J Refract Surg1999; 15: 711–3.
15.
KashiwabuchiR.T., CarvalhoF.R., KhanY.A.. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites.Invest Ophthalmol Vis Sci2011; 52: 9333–8.
16.
Del BueyM.A., CristóbalJ.A., CasasP.. Evaluation of in vitro efficacy of combined riboflavin and ultraviolet a for Acanthamoeba isolates.Am J Ophthalmol2012; 153: 399–404.
GirgisD.O., KarpC.L., MillerD.. Ocular infections caused by non-tuberculous mycobacteria: update on epidemiology and management.Clin Experiment Ophthalmol2012; 40: 467–75.
19.
De la CruzJ., PinedaRII. LASIK-associated atypical mycobacteria keratitis: a case report and review of the literature.Int Ophthalmol Clin2007; 47: 73–84.
20.
BottoneE.J., ChoK.W.. Mycobacterium chelonae keratitis: elucidation of diagnosis through evaluation of smears of fluid from patient's contact lens care system.Cornea2005; 24: 356–8.
21.
SrinivasanM., PrajnaL., PrajnaN.V.. A cluster of cases of Mycobacterium chelonae keratitis following penetrating keratoplasty.Indian J Ophthalmol2005; 53: 67–8.
22.
ReviglioV., RodriguezM.L., PicottiG.S.. Mycobacterium chelonae keratitis following laser in situ keratomileusis.J Refract Surg1998; 14: 357–60.
23.
ChangM.A., JainS., AzarD.T.. Infections following laser in situ keratomileusis: an integration of the published literature.Surv Ophthalmol2004; 49: 269–80.
24.
KarpC.L., TuliS.S., YooS.H.. Infectious keratitis after LASIK.Ophthalmology2003; 110: 503–10.
25.
SolomonA., KarpC.L., MillerD., DubovyS.R., HuangA.J., CulbertsonW.W.. Mycobacterium interface keratitis after laser in situ keratomileusis.Ophthalmology2001; 108: 2201–8.
26.
FreitasD., AlvarengaL., SampaioJ.. An outbreak of Mycobacterium chelonae infection after LASIK.Ophthalmology2003; 110: 276–85.
